Additionally, the 36-month beta value for YMAB is 0.66. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for YMAB is 37.00M and currently, short sellers hold a 10.85% ratio of that float. The average trading volume of YMAB on November 13, 2024 was 266.60K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
YMAB) stock’s latest price update
The stock of Y-Mabs Therapeutics Inc (NASDAQ: YMAB) has decreased by -11.37 when compared to last closing price of 14.87.Despite this, the company has seen a loss of -12.72% in its stock price over the last five trading days. zacks.com reported 2024-11-08 that Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.18 per share a year ago.
YMAB’s Market Performance
YMAB’s stock has fallen by -12.72% in the past week, with a monthly drop of -9.35% and a quarterly rise of 10.11%. The volatility ratio for the week is 10.95% while the volatility levels for the last 30 days are 6.03% for Y-Mabs Therapeutics Inc The simple moving average for the past 20 days is -10.69% for YMAB’s stock, with a -4.67% simple moving average for the past 200 days.
Analysts’ Opinion of YMAB
Many brokerage firms have already submitted their reports for YMAB stocks, with Cantor Fitzgerald repeating the rating for YMAB by listing it as a “Overweight.” The predicted price for YMAB in the upcoming period, according to Cantor Fitzgerald is $20 based on the research report published on August 16, 2024 of the current year 2024.
Truist, on the other hand, stated in their research note that they expect to see YMAB reach a price target of $21. The rating they have provided for YMAB stocks is “Buy” according to the report published on June 28th, 2024.
Wedbush gave a rating of “Outperform” to YMAB, setting the target price at $13 in the report published on May 10th of the previous year.
YMAB Trading at -6.55% from the 50-Day Moving Average
After a stumble in the market that brought YMAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.94% of loss for the given period.
Volatility was left at 6.03%, however, over the last 30 days, the volatility rate increased by 10.95%, as shares sank -7.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.04% lower at present.
During the last 5 trading sessions, YMAB fell by -12.72%, which changed the moving average for the period of 200-days by +8.84% in comparison to the 20-day moving average, which settled at $14.76. In addition, Y-Mabs Therapeutics Inc saw 93.26% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at YMAB starting from Gad Thomas, who sale 65,000 shares at the price of $13.47 back on Sep 13 ’24. After this action, Gad Thomas now owns 97,681 shares of Y-Mabs Therapeutics Inc, valued at $875,550 using the latest closing price.
Gad Thomas, the CHIEF BUSINESS OFFICER of Y-Mabs Therapeutics Inc, sale 30,000 shares at $12.97 during a trade that took place back on Sep 16 ’24, which means that Gad Thomas is holding 67,681 shares at $389,100 based on the most recent closing price.
Stock Fundamentals for YMAB
Current profitability levels for the company are sitting at:
- -0.34 for the present operating margin
- 0.91 for the gross margin
The net margin for Y-Mabs Therapeutics Inc stands at -0.28. The total capital return value is set at -0.3. Equity return is now at value -24.78, with -19.11 for asset returns.
Based on Y-Mabs Therapeutics Inc (YMAB), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -20.35. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -22.01.
Currently, EBITDA for the company is -20.45 million with net debt to EBITDA at 2.4. When we switch over and look at the enterprise to sales, we see a ratio of 6.15. The receivables turnover for the company is 4.25for trailing twelve months and the total asset turnover is 0.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.92.
Conclusion
In conclusion, Y-Mabs Therapeutics Inc (YMAB) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
